SAPHO syndrome successful treated with tildrakizumab
Dermatol Ther
.
2021 Jan;34(1):e14758.
doi: 10.1111/dth.14758.
Epub 2021 Jan 11.
Authors
Gaetano Licata
1
,
Alessio Gambardella
1
,
Giulia Calabrese
1
,
Roberto Alfano
2
,
Giuseppe Argenziano
1
Affiliations
1
Dermatology Unit, Department of Mentals and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
2
Department of Anesthesiology, Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy.
PMID:
33405331
DOI:
10.1111/dth.14758
No abstract available
Publication types
Letter
MeSH terms
Acquired Hyperostosis Syndrome* / diagnosis
Acquired Hyperostosis Syndrome* / drug therapy
Antibodies, Monoclonal, Humanized
Humans
Substances
Antibodies, Monoclonal, Humanized
tildrakizumab